Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
Patients with type 2 diabetes on intensive lipid lowering therapy may be at an increased risk for developing secondary neuropathies, based on the results of a recent study.
Read More »Intensive Lipid Lowering Linked To Neuropathy
Low-carb Diet Without Calorie Restriction Favorable on Metabolic Syndrome
A recent study compared three equicaloric diets with varying carbohydrate intake amounts for their effect on metabolic syndrome risk factors.
Read More »Evidence for Lack of a Glucose-Control Legacy Effect
Intensive glycemic control shows benefits with time; however, evidence is showing this effect may wear off.
Read More »How the Tongue Can Be Used As A Possible Preliminary Diabetes Screening Tool
A furry or bluish tongue may indicate type 2 diabetes, according to a recent study.
Read More »Renal Outcomes After Canagliflozin Use in Patients with Type 2 Diabetes
Diabetes mellitus is the leading cause of end-stage renal disease (ESRD) worldwide.
Read More »Antidepressants Reduce Mortality For Patients With Diabetes And Depression
Both type 1 and type 2 diabetes increase the risk of depression.
Read More »Promising Results In A Phase 3 First-in-Class Oral Diabetic Drug
How does Imeglimin perform in combination with metformin in patients with type 2 diabetes?
Read More »Can Chronic Kidney Disease Cause Type 2 Diabetes?
Study examines why type 2 diabetes incident rate is higher in patients with chronic kidney disease.
Read More »PIONEER 5 Study Validates Oral GLP-1 Effectiveness
The PIONEER 5 study discusses the safety and efficacy of the first oral GLP-1 receptor agonist, a potential substitute to injections.
Read More »The CARMELINA Trial: Linagliptin’s Cardiovascular Effects for Type 2 Diabetes with High Cardiorenal Risk — ADA 2019
The CARMELINA trial demonstrated noninferiority of linagliptin compared with placebo in CV events in high risk people with type 2 diabetes.
Read More »